Funder
National Institutes of Health
Cystic Fibrosis Foundation
National Center for Advancing Translational Sciences
Subject
Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health
Reference17 articles.
1. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809;Van Goor;Proc Natl Acad Sci U S A,2011
2. Van Goor F., Grootenhuis P., Hadida S., Burton B., Young T., Selkirk J., Powe A., De La Rosa O., Jiang L., Zhou J. Nonclinical profile of the CFTR corrector VX-661. Pediatric Pulmonology: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. p. 274–.
3. Effects of Lumacaftor-Ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis;Graeber;Ann Am Thorac Soc,2021
4. Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del;Taylor-Cousar;N Engl J Med,2017
5. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR;Wainwright;N Engl J Med,2015